Hadron Therapy Workshop: status and perspectives, plans for next generation facilities 18-19 October 2024

Contribution List

82. Participants registration

18/10/2024, 08:00

SESSION 1 - HADRON THERAPY OVERVIEW

83. Welcome Addresses

18/10/2024, 08:45

SESSION 1 - HADRON THERAPY OVERVIEW

Maria Bigaki (IAEA CP, Papageorgiou), Michail Karaviotis ( Papageorgiou),
Sotirios Charisopoulos (IAEA), Sandro Rossi (HITRIplus, CNAO),
Panagiotis Bamidis (AUTH,/AHEPA, ELEVIT)

84. Historic and scientific evolution of Hadron Therapy

Ugo Amaldi (TERA Foundation (IT)), Sandro Rossi (CNAO)

18/10/2024, 09:15

SESSION 1 - HADRON THERAPY OVERVIEW

85. Hadron Therapy in clinical practice

Sara Lillo (CNAO)

18/10/2024, 09:35

SESSION 1 - HADRON THERAPY OVERVIEW

86. Radiobiology of Hadron Therapy

Angelica Facoetti (CNAO)

18/10/2024, 09:55

SESSION 1 - HADRON THERAPY OVERVIEW

87. HITRIplus project, its impact on boosting research in South East Europe and future perspectives

Sanja Damjanovic (SEEIIST Association (CH) / GSI)

18/10/2024, 10:15

SESSION 1 - HADRON THERAPY OVERVIEW

88. Building capacity through the IAEA programs

Sotirios Charisopoulos (IAEA)

18/10/2024, 10:35

SESSION 1 - HADRON THERAPY OVERVIEW

90. Hadron Therapy : from pioneering times towards the future

Manjit Dosanjh (University of Oxford (GB))

18/10/2024, 11:30

SESSION 2 – HADRON THERAPY DEVELOPMENTS AND FUTURE PERSPECTIVES

93. SEEIIST facility design and alternatives

Maurizio Vretenar (CERN)

18/10/2024, 11:50

SESSION 2 – HADRON THERAPY DEVELOPMENTS AND FUTURE PERSPECTIVES

95. CERN as an example of large scale infrastructure

Emmanuel Tsesmelis (CERN)

18/10/2024, 12:10

SESSION 2 – HADRON THERAPY DEVELOPMENTS AND FUTURE PERSPECTIVES

97. Status and vision of the SEEIIST project

Leandar Litov (University of Sofia - St. Kliment Ohridski (BG))

18/10/2024, 12:30

SESSION 2 – HADRON THERAPY DEVELOPMENTS AND FUTURE PERSPECTIVES

101. Concluding remarks

Roberto Orecchia (IEO)

18/10/2024, 12:50

SESSION 2 – HADRON THERAPY DEVELOPMENTS AND FUTURE PERSPECTIVES

100. Round table – SEEIIST towards to the Future

18/10/2024, 13:00

SESSION 2 – HADRON THERAPY DEVELOPMENTS AND FUTURE PERSPECTIVES

Moderators: Sotirios Charisopoulos (IAEA), Sandro Rossi (HITRIplus, CNAO)
Panelists: Maurizio Vretenar (CERN), Semi Harrabi (HIT)
Contributions: Introduction, cancer incidence in SEE Mimoza Ristova (Uni Skopje)

105. Hadron Therapy at GSI - where we come from, where we go

Konrad Lehmann (GSI)

18/10/2024, 15:00

SESSION 3 – EXPERIENCES OF MULTIPARTICLE THERAPY FACILITIES IN OPERATION IN EUROPE

106. The HIT facility, technology, clinical applications and research: novel approaches in particle therapy

Andrea Mairani (HIT)

18/10/2024, 15:25

SESSION 3 – EXPERIENCES OF MULTIPARTICLE THERAPY FACILITIES IN OPERATION IN EUROPE

112. The Krakow Hadron Therapy facility, lessons learnt

Pawel Olko (IFJ - PAN)

18/10/2024, 15:50

SESSION 3 – EXPERIENCES OF MULTIPARTICLE THERAPY FACILITIES IN OPERATION IN EUROPE

127. Concluding remarks

Angelica Facoetti (CNAO)

18/10/2024, 16:15

SESSION 3 – EXPERIENCES OF MULTIPARTICLE THERAPY FACILITIES IN OPERATION IN EUROPE

115. Accelerator and beam physics developments for medical and societal applications at CERN

Alessandra Lombardi (CERN)

18/10/2024, 17:00

SESSION 4 – ADVANCES IN ACCELERATOR TECHNOLOGIES FOR HADRON THERAPY FACILITIES

118. Innovative gantry designs: Superconducting magnets for advanced gantry

Ernesto De Matteis (INFN)

18/10/2024, 17:20

SESSION 4 – ADVANCES IN ACCELERATOR TECHNOLOGIES FOR HADRON THERAPY FACILITIES

136. Innovative gantry designs-continued

Ariel Haziot (CERN)

18/10/2024, 17:35

SESSION 4 – ADVANCES IN ACCELERATOR TECHNOLOGIES FOR HADRON THERAPY FACILITIES

116. Optimisation for pre-injectors for hadron therapy-AM

Aristeidis Mamaras (Aristotle University of Thessaloniki / CERN)

18/10/2024, 17:50

SESSION 4 – ADVANCES IN ACCELERATOR TECHNOLOGIES FOR HADRON THERAPY FACILITIES

119. An ion source project as a seed to build capacity for next generation accelerator physicists in Bosnia-and-Herzegovina

Amer Ajanovic (CERN/UNSA), Danis Bradaric (UNSA), Medina Dugonjic (UNSA), Naida Ustavdic (UNSA)

18/10/2024, 18:10

SESSION 4 – ADVANCES IN ACCELERATOR TECHNOLOGIES FOR HADRON THERAPY FACILITIES

138. Development of the first table-top X-ray FLASH system

Ms ELPIDA THEODORIDOU (DKFZ / Uni Malta), Joao Seco (DKFZ)

18/10/2024, 18:25

SESSION 4 – ADVANCES IN ACCELERATOR TECHNOLOGIES FOR HADRON THERAPY FACILITIES

124. Concluding remarks

Laura Vallow (Mayo Clinic)

18/10/2024, 18:40

SESSION 4 – ADVANCES IN ACCELERATOR TECHNOLOGIES FOR HADRON THERAPY FACILITIES

126. Welcome, Music event and Welcome Drink

18/10/2024, 20:00

SESSION 4 – ADVANCES IN ACCELERATOR TECHNOLOGIES FOR HADRON THERAPY FACILITIES

Concert and Welcome Drink

91. Chordoma treatments at CNAO

Maria Rosaria Fiore (CNAO)

19/10/2024, 09:00

Session 5 – INDICATIONS FOR HADRON THERAPY

92. Sarcoma treatments in Greece

Tasos Kyriazoglou (Attikon University Hospital)

19/10/2024, 09:25

Session 5 – INDICATIONS FOR HADRON THERAPY

94. Radiosurgery for Skullbase Meningiom

Christos Boskos (ST. LUKE'S)

19/10/2024, 09:45

Session 5 – INDICATIONS FOR HADRON THERAPY

96. SRS Treatment Planning for Endocranial Tumor

Anna Makridou

19/10/2024, 10:05

Session 5 – INDICATIONS FOR HADRON THERAPY

98. Personalization of hadron therapy for radioresistant cancers through bioindicators of radioresistance or conditional vulnerability

Michael Story (Mayo Clinic)

19/10/2024, 10:25

Session 5 – INDICATIONS FOR HADRON THERAPY

99. Concluding remarks

Arnold Pompos (UT Southwestern, Dallas, TX), Joao Seco (DKFZ)

19/10/2024, 10:50

Session 5 – INDICATIONS FOR HADRON THERAPY

102. Hadrontherapy and EU clinical networks: status and perspectives

Lisa Licitra (CNAO, Uni Milan)

19/10/2024, 11:30

SESSION 6 – SOCIO-ECONOMIC ASPECTS RELATED TO HADRON THERAPY

103. Costs of hadrontherapy, the ABC analysis applied to operations in CNAO

Maria Vittoria Livraga (CNAO)

19/10/2024, 11:50

SESSION 6 – SOCIO-ECONOMIC ASPECTS RELATED TO HADRON THERAPY

104. Caring for cancer patients: the CNAO social approach

Silvia Meneghello (CNAO)

19/10/2024, 12:10

SESSION 6 – SOCIO-ECONOMIC ASPECTS RELATED TO HADRON THERAPY

107. The role of citizens in innovating health

Katerina Zourou (Web2Learn), Stefania Oikonomou (Web2Learn)

19/10/2024, 12:30

SESSION 6 – SOCIO-ECONOMIC ASPECTS RELATED TO HADRON THERAPY

110. The role of biomedical and clinical engineering societies in advancing and promoting Hadron Therapy on a national and international level

Alkinoos Athanasiou (AUTH, ELEVIT)

19/10/2024, 12:45

SESSION 6 – SOCIO-ECONOMIC ASPECTS RELATED TO HADRON THERAPY

111. Challenges and Opportunities in the Patient's Pathway to Access

Menia Koukougianni (NGO KARKINAKI)

19/10/2024, 13:00

SESSION 6 – SOCIO-ECONOMIC ASPECTS RELATED TO HADRON THERAPY

108. Empowering patient advocacy and cancer prevention

Panagiotis Bamidis (AUTH/AHEPA, ELEVIT)

19/10/2024, 13:20

SESSION 6 – SOCIO-ECONOMIC ASPECTS RELATED TO HADRON THERAPY

113. Concluding remarks

Sandro Rossi (CNAO)

19/10/2024, 13:35

SESSION 6 – SOCIO-ECONOMIC ASPECTS RELATED TO HADRON THERAPY

128. Carbon Programme in MedAustron

Piero Fossati (MedAustron)

19/10/2024, 15:00

SESSION 7 – PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

129. Pediatric Treatments in MedAustron

Carola Lütgendorf-Caucig (MedAustron)

19/10/2024, 15:15

SESSION 7 – PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

117. Hadron therapy state-of-the art in pediatric oncology-clinical aspects

Sabina Vennarini (CNAO)

19/10/2024, 15:30

SESSION 7 – PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

120. Treatment planning for pediatric cancer tumour treatments

Alfredo Mirandola (CNAO)

19/10/2024, 15:45

SESSION 7 – PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

130. Pediatric brain tumour surgery : where do we stand?

Nikos Foroglou (AUTH/AHEPA)

19/10/2024, 16:00

SESSION 7 – PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

131. Role of surgery in pediatric soft tissue sarcoma

Aikaterini Tzantzaroudi (Hippokration Hospital)

19/10/2024, 16:15

SESSION 7 – PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

125. Panel discussion: Paediatric Oncology in Greece

19/10/2024, 17:00

SESSION 7 – PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

132. Clinical profile of pediatric oncology patients managed and treated in Pediatric Haematology and/or Oncology Unit University Hospital AHEPA

Emmanouel Chatzipantelis (AUTH/AHEPA)

19/10/2024, 17:01

SESSION 7 – PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

133. Clinical profile of pediatric oncology patients managed and treated in Pediatric Haematology and/or Oncology Unit Hospital Hippoktateio Hospital

Evgenia Papakonstantinou (Hippokrateio Hospital)

19/10/2024, 17:15

SESSION 7 – PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

123. Pediatric patients commonly referred for external beam Radiotherapy

Antonio Capizzello (AUTH / AHEPA), Eftychia Tataridou (Theageneio Hospital)

19/10/2024, 17:30

SESSION 7 – PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

121. The spectrum of pediatric patients referred for Protontherapy

Barbara Rombi (APSS - TRENTO)

19/10/2024, 17:45

SESSION 7 – PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

134. Radiation treatment plan for pediatric cancer: a clinical view

George Giakoumetis (AUTH/AHEPA)

19/10/2024, 18:00

SESSION 7 – PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

135. Concluding remarks

Semi Harrabi (HIT)

19/10/2024, 18:15

SESSION 7 – PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

Back to the event